This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Feuerstein's Biotech-Stock Mailbag: Elan

(Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco. Adam will be speaking to attendees on Friday, Aug. 8, at 2:15 p.m. ("Biotech Investing for Individuals: How to Turn Geeky Science Into Fat Profits"); on a lunch panel on Saturday, Aug. 9, at 12:35 p.m. ("Tech and Biotech: Picks and Pans for 2008 and Beyond"); and on Sunday, Aug. 10, at 8 a.m. ("Biotech Investing for Individuals: How to Turn Geeky Science Into Fat Profits").

This column originally posted on at 8:58 a.m. EDT. For more information about subscribing to RealMoney , please click here.

What a crazy week! The Biotech Mailbag is brimming with email, so let's get to it.

The big story, of course, was the meltdown of Elan (ELN) Wednesday after its Alzheimer's drug fell flat on its face at the International Conference on Alzheimer's Disease meeting in Chicago.

I've been a vocal skeptic of Elan and its Alzheimer's drug bapineuzumab this year, a bearish position that hasn't always been a comfortable one to take. Needless to say, I felt vindicated and it was nice to receive a bunch of emails acknowledging my work.

"You were right on target. Props," wrote Charles B.

From Vince M.: "Congrats on the Elan call. You were right."

I even heard from an Elaniac, a guy known only as snugpharma. "Today, you win. In the future, well, in this chastened mood, I am not really up for the fight at this time."

Enough back-slapping. Most of the email I received on Elan this week was from readers who want to know what happens next, like Gerry W., who wrote:
"Hey Adam, the Elan column was a great read. I'm wondering, however, what happens to the company and the stock now that the [ICAD] conference is over?"

Gerry's email arrived before Thursday's night bombshell, when Biogen Idec (BIIB - Get Report) and Elan disclosed in a regulatory filing two new cases of a serious and often deadly brain infection in multiple sclerosis patients being treated with Tysabri. In fact, I wrote this entire column before the Tysabri news hit the wires.

In version one of this week's Mailbag, written with the sun high on a hot and humid Thursday afternoon, I intended to tell Gerry that Elan was in a real bind because of bapineuzumab. It's late Thursday night, dark but still hot and humid, as I rework Mailbag version No. 2 to reflect the Tysabri situation.

Needless to say, Elan's outlook doesn't look any brighter.

Is there any compelling reason to own Elan now? Bapineuzumab looks like a crapshoot at best, and news flow around the program goes dark as the phase III studies enroll patients and we wait two years for data. Many bulls were hoping for an early or accelerated approval filing. Please, the bapineuzumab data are so weak, that rosy scenario is now pure fantasy.
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
BIIB $263.54 -0.41%
BMRN $80.75 0.01%
GILD $84.69 -1.40%
MYGN $34.33 0.41%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs